Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01695005 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3039478 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 247
- Enrollment target
NCT01695005 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 247 participants.
The verdict
NCT01695005, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 247 participants
- Enrollment target
Study Summary
The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma. The study will also explore changes to various markers in blood cells and tissue. Finally, the study will help to document any tumor activity this drug may have.
Interventions
- DRUG Prednisone
- DRUG LY3039478
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01695005
The ClinicalTrials.gov registry entry for NCT01695005 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT01695005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01695005 about?
NCT01695005 is a clinical study titled "A Study of LY3039478 in Participants With Advanced Cancer". The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma. The study will also explore changes to various markers in blood cells ...
What is the current status of trial NCT01695005?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 247 participants. The study started on 2012-10. Estimated completion is 2018-06-26.
What interventions are being tested in trial NCT01695005?
The interventions under investigation include: Prednisone (DRUG), LY3039478 (DRUG).
Who is sponsoring clinical trial NCT01695005?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.